Castle Biosciences (CSTL) Projected to Post Quarterly Earnings on Thursday

Castle Biosciences (NASDAQ:CSTL) is expected to issue its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $81.1890 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Castle Biosciences Trading Up 0.7%

Shares of CSTL opened at $33.67 on Thursday. Castle Biosciences has a fifty-two week low of $14.59 and a fifty-two week high of $44.28. The company has a market capitalization of $982.83 million, a PE ratio of -74.82 and a beta of 1.06. The stock has a fifty day moving average of $38.40 and a two-hundred day moving average of $30.66. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.47.

Analysts Set New Price Targets

A number of research firms have recently commented on CSTL. Guggenheim upped their price objective on shares of Castle Biosciences from $43.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, February 2nd. KeyCorp reiterated an “overweight” rating and issued a $50.00 price target on shares of Castle Biosciences in a report on Thursday, January 29th. Canaccord Genuity Group boosted their price objective on shares of Castle Biosciences from $37.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Finally, BTIG Research increased their target price on Castle Biosciences from $38.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $47.14.

Insiders Place Their Bets

In other Castle Biosciences news, COO Kristen M. Oelschlager sold 14,888 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $39.31, for a total transaction of $585,247.28. Following the transaction, the chief operating officer owned 12,323 shares in the company, valued at $484,417.13. The trade was a 54.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Derek J. Maetzold sold 817 shares of the company’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $37.99, for a total value of $31,037.83. Following the completion of the sale, the insider directly owned 83,698 shares of the company’s stock, valued at $3,179,687.02. The trade was a 0.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 34,732 shares of company stock valued at $1,372,743. 6.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Castle Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CSTL. RTW Investments LP acquired a new stake in Castle Biosciences during the 4th quarter valued at approximately $82,283,000. Dimensional Fund Advisors LP raised its holdings in Castle Biosciences by 7.0% in the third quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company’s stock valued at $33,564,000 after acquiring an additional 96,084 shares in the last quarter. Wasatch Advisors LP boosted its stake in Castle Biosciences by 5.1% during the 2nd quarter. Wasatch Advisors LP now owns 1,049,773 shares of the company’s stock valued at $21,436,000 after acquiring an additional 51,318 shares during the last quarter. State Street Corp grew its holdings in Castle Biosciences by 1.7% during the 4th quarter. State Street Corp now owns 736,454 shares of the company’s stock worth $28,648,000 after acquiring an additional 12,374 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Castle Biosciences by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 714,913 shares of the company’s stock worth $27,815,000 after purchasing an additional 16,303 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.